One of these is legal. The other lost more weight.
If you have been comparing tesofensine and phentermine, you have probably run into the same two numbers everywhere: tesofensine produced around 10% weight loss in a trial, phentermine produces around half that. That comparison is real, but it is missing the context that decides which one you can actually use — and one detail about the tesofensine trial that almost nobody mentions.
🔑 Key Takeaways
- Both work on brain chemistry rather than gut hormones, which makes them a different category from GLP-1 drugs entirely.
- Tesofensine hits three neurotransmitter systems; phentermine essentially hits one. That difference explains both the efficacy gap and the side effects.
- The headline tesofensine number comes from a single phase II trial — and that trial carries a formal Expression of Concern from the journal that published it.
- Phentermine is prescribable in the US and has sixty-five years of use behind it. Tesofensine finished phase 3 in Mexico in 2018 and still is not approved anywhere.
- Comparing the two on weight loss alone gets you the wrong answer. The section on availability is the one that decides it.
For the full picture on one side of this comparison, see our complete tesofensine guide.
Tesofensine vs Phentermine at a Glance
| Tesofensine | Phentermine | Why it matters | |
|---|---|---|---|
| Mechanism | Triple reuptake inhibitor — noradrenaline, dopamine, serotonin | Sympathomimetic — primarily noradrenaline release | Three systems versus one drives both the effect and the side effects |
| Best trial result | 10.6% at 1.0 mg over 24 weeks | 8.1 kg at 30 mg over 12 weeks | Different trial designs; not a like-for-like comparison |
| Trial size | 203 patients, phase II | 74 patients, 12 weeks | Both small by modern obesity-trial standards |
| FDA status | Not approved | Approved 1959, short-term use, Schedule IV | The single biggest practical difference |
| Duration of use | 24 weeks in trial; not established in practice | Labelled for short-term use, typically up to 12 weeks | Neither has long-term approval |
| Main side effects | Dry mouth, nausea, constipation, insomnia, raised heart rate | Dry mouth, insomnia | Overlapping, with heart rate the notable tesofensine signal |
How Each One Works
Both raise the same class of signal, but not by the same route.
Phentermine is a sympathomimetic amine. It prompts the release of noradrenaline, which suppresses appetite through hypothalamic pathways. It is a close structural relative of amphetamine, which is why it is a controlled substance and why insomnia and a dry mouth are the two things almost everyone taking it notices.
Tesofensine blocks reuptake of three neurotransmitters at once — noradrenaline, dopamine and serotonin. Rather than pushing more signal out, it stops what is already released from being cleared. The dopamine component is what distinguishes it: it is thought to act on reward and food-seeking, not just hunger.
There is a footnote worth knowing. Tesofensine was not designed as a weight-loss drug at all. It was developed for Parkinson's disease and Alzheimer's, failed to deliver in those, and the weight loss observed along the way became the reason anyone still talks about it.
Weight Loss Results Compared
Here are the actual trials, not the summaries of them.
Tesofensine — Astrup and colleagues, The Lancet, 2008. A phase II trial: 203 patients with obesity, 24 weeks, energy-restricted diet, randomised to 0.25 mg, 0.5 mg, 1.0 mg or placebo.
| Group | Dose | Duration | Mean weight loss | Above placebo |
|---|---|---|---|---|
| Placebo + diet | — | 24 weeks | 2.0% | — |
| Tesofensine low | 0.25 mg | 24 weeks | 4.5% | +2.5 points |
| Tesofensine mid | 0.5 mg | 24 weeks | 9.2% | +7.2 points |
| Tesofensine high | 1.0 mg | 24 weeks | 10.6% | +8.6 points |
The authors concluded that 0.5 mg "might have the potential to produce a weight loss twice that of currently approved drugs" — and explicitly said the finding needed confirmation in phase III. That confirmation came a decade later, and not in Europe or the US — see the phase 3 section below.
Phentermine — Kang and colleagues, Diabetes, Obesity and Metabolism, 2010. A 12-week randomised trial of a controlled-release 30 mg formulation in 74 patients.
- Weight loss of 8.1 kg versus 1.7 kg on placebo.
- 95.8% of the phentermine group lost 5% or more of body weight, against 20.8% on placebo.
- 62.5% lost 10% or more, against 4.7% on placebo.
- No significant difference in blood pressure between groups.
Note the units differ — one trial reported percentage, the other kilograms — and the durations differ by half. Anyone presenting "10.6% versus 8.1 kg" as a clean head-to-head is comparing two things that were never measured the same way.
The Problem With the Tesofensine Data
This is the part the comparison articles leave out.
In April 2013, The Lancet published a formal Expression of Concern regarding the 2008 tesofensine trial. An Expression of Concern is what a journal issues when questions have been raised about a paper that it considers serious enough to flag to readers, without retracting it.
The 2008 trial is the source of essentially every tesofensine weight-loss figure in circulation, including the ones at the top of this page. That its publishing journal thought readers should be warned about it is a material fact about the quality of the evidence, and it belongs in any honest comparison.
What this does and does not mean: an Expression of Concern is not a retraction and not a finding of fraud. The paper stands. But it means the single trial underpinning tesofensine's reputation carries a formal caution from its own journal. A larger phase 3 trial did eventually report a similar result, which cuts the other way — but it was run by the licence holder in a single country and has never been published in a peer-reviewed journal. Weigh the 10.6% figure accordingly.
Side Effects Compared
They overlap more than the mechanisms suggest.
Both reliably produce dry mouth and insomnia. That is the signature of raising noradrenergic tone, and it is the most common reason people stop taking either one.
Tesofensine adds nausea, constipation and hard stools, plus a cardiovascular signal worth taking seriously: heart rate rose by 7.4 beats per minute in the 0.5 mg group. At 0.25 mg and 0.5 mg there was no significant blood pressure increase, but the heart rate effect was real and dose-related.
Phentermine's profile is better characterised simply because it has been in use since 1959. In the 12-week trial above, adverse events were described as mild to moderate and transient, with no significant blood pressure difference from placebo.
Legal Status and Availability
This is what actually decides it.
Phentermine is FDA-approved, prescribable in the United States, and a Schedule IV controlled substance. It is labelled for short-term use, generally up to 12 weeks, as an adjunct to diet and exercise. Getting it means seeing a clinician who can prescribe it.
Tesofensine has no FDA approval. Its phase 3 trial was run in Mexico by licence holder Medix and reported in 2018: 372 patients over 24 weeks on 0.25 mg or 0.50 mg, roughly 10% average weight loss, with more than half of those treated losing over 10% of body weight. Mexico's regulator COFEPRIS issued a favourable technical opinion in February 2023 — but that opinion is explicitly non-binding and is not a marketing authorisation. As of the most recent company updates the application was still being revised and resubmitted, so tesofensine remains approved nowhere. Outside a prescription route it shows up two ways: as unlabelled powder from online sellers, and in low-dose capsule formulas that combine a fraction of a trial dose with other ingredients — BioFlow pairs 250 mcg of tesofensine with taurine and magnesium L-threonate. The formulated version at least tells you the dose. Neither route involves a clinician monitoring your heart rate, and with loose powder both purity and dose accuracy depend entirely on the seller.
That asymmetry outweighs a few percentage points of trial weight loss for most people. A drug you can obtain through a clinician who monitors your heart rate is a different proposition from a capsule ordered from a website.
Which One Makes Sense
For most people, phentermine — and not because it works better.
It works somewhat less well on the raw trial numbers. But it is prescribable, its safety profile is documented across six decades, and using it means someone qualified is watching your blood pressure and heart rate. Tesofensine offers a modestly better number from one small trial that its own journal has flagged.
Worth saying plainly: both are appetite suppressants that work on brain chemistry, and both are short-term tools. Neither addresses what happens when you stop. If you are choosing between them because GLP-1 drugs are out of reach on cost, that is a different comparison worth running properly — our guide to GLP-1 medications covers what those actually cost now, and appetite suppressant options covers the wider field.
If you have already decided on tesofensine, our tesofensine dosage guide covers protocols and cycling, and tesofensine for weight loss goes deeper on how it compares with GLP-1 drugs specifically.
Frequently Asked Questions
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new supplement, medication, or treatment. PeptideDeck may earn a commission from affiliate links at no additional cost to you.
